Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

11. LOANS RECEIVABLE (Details)

v3.21.2
11. LOANS RECEIVABLE (Details) - CAD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Loans receivable [1] $ 51,676,623 $ 36,504,397  
Revaluation of financial instruments (673,585) 0  
Tidal and MichiCann      
Net identifiable assets acquired, Promissory note receivable [2] 4,169,009    
Advances to PharmaCo Inc      
Loans receivable 11,084,278 4,381,329  
Promissory note receivable from PharmaCo Inc      
Loans receivable 32,627,616 30,648,517  
Promissory note acquired with RTO      
Loans receivable [2] 4,231,664 0  
Accrued interest on promissory note acquired with RTO      
Loans receivable [2] 686,288 0  
Net receivable from sellers of Platinum Vape      
Loans receivable [3] 3,046,777 0  
Settlement of preexisting relationship in MAG acquisition      
Loans receivable [3] $ 0 1,474,551  
Advances to PharmaCo Inc #1      
Long-term Debt   $ 4,381,329 $ 4,810,000
Advances to PharmaCo Inc #2      
Debt Instrument, Description Company issued 2,339,200 units consisting of one common share and one convertible series II preferred share    
Promissory note receivable from PharmaCo Inc #1      
Debt Instrument, Description Company entered a Promissory Note Agreement (“Promissory Note”) with PharmaCo    
Promissory note receivable from PharmaCo Inc #2      
Debt Instrument, Description Company advanced a principal amount of $1,979,099    
Promissory note acquired with RTO #1      
Debt Instrument, Description promissory note of value of $4,169,009 was acquired pursuant to the RTO transaction    
[1] Note 11.
[2] Note 5.
[3] Note 6.